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Abstract: Acne vulgaris is a common and chronic skin disease, and is a frequent source of 
morbidity for affected patients. Treatment of acne vulgaris is often difficult due to the multi-
factorial nature of this disease. Combination therapy, such as that containing clindamycin and 
benzoyl peroxide, has become the standard of care. Several fixed formulations of clindamycin 
1% and benzoyl peroxide of varying concentrations are available and have been used with con-
siderable success. The major limitation is irritation and dryness from higher concentrations of 
benzoyl peroxide, and a combination providing optimal efficacy and tolerability has yet to be 
determined. Recently, a clindamycin and benzoyl peroxide 3.75% fixed combination formulation 
was developed. Studies have suggested that this formulation may be a safe and effective treatment 
regimen for patients with acne vulgaris. Here, we provide a brief review of acne pathogenesis, 
benzoyl peroxide and clindamycin, and profile a new Clindamycin-BP 3.75% fixed combination 
gel for the treatment of moderate-to-severe acne vulgaris.
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Introduction
Acne vulgaris is a common and chronic skin disease affecting millions of people 
worldwide. It is the most common skin disorder in the USA and is the number one 
reason for visiting a dermatologist.1 It is a common source of morbidity, and a variety 
of topical and systemic medications have been developed to treat acne.  However, 
because of the multifactorial nature of acne, effective treatment is often difficult to 
obtain. Combination therapies targeting different aspects of acne pathogenesis have 
become the standard of care.2 Treatment with topical clindamycin in combination with 
benzoyl peroxide (BP) has been found to be superior to either medication alone.3 This 
combination appears to target both inflammatory and noninflammatory acne, and as 
such, has become a major treatment option for patients with acne. Several fixed for-
mulations of clindamycin 1% and BP (varying concentrations) have been used with 
considerable success.4–7 The major limitation associated with many fixed combinations 
is irritation and dryness from higher concentrations of BP.8 Here, we will provide a 
brief overview of acne pathogenesis, background on the use of BP and clindamycin, 
and profile a new clindamycin–BP 3.75% fixed combination gel for the treatment of 
moderate-to-severe acne vulgaris.
Background on acne vulgaris
Acne vulgaris is the most common cutaneous disorder worldwide. It is particularly 
common in adolescents and young adults and is often a significant source of anxiety, 





embarrassment, and psychosocial morbidity for affected 
patients.9 Although most cases of acne vulgaris are self-
limited or responsive to topical medications alone, severe 
cases may last well into adulthood and may be associated 
with scarring, persistent hyperpigmentation, and significant 
psychosocial consequences.2 Clinically, acne is character-
ized by a combination of noninflammatory open and closed 
comedones and inflammatory papules and pustules, typically 
affecting areas with a high proportion of sebaceous follicles, 
such as the face, chest, and back.
The pathogenesis of acne vulgaris is a multifactorial 
process, involving follicular hyperkeratinization and obstruc-
tion, increased sebum production, Propionibacterium acnes 
colonization, and inflammation.10 One of the major factors 
in the early formation of acne appears to be sebaceous fol-
licle obstruction caused by follicular hyperkeratinization and 
deposition of keratinocytes in the follicle orifice leading to 
microcomedones.10,11 The cause and pathogenesis of follicular 
hyperkeratinization is still not completely understood. It is 
thought to be associated with changing hormonal influences 
during puberty. Higher levels of dihydrotestosterone have 
been found to act on infundibular keratinocytes, contributing 
to the hyperkeratinzation seen in acne pathogenesis.12 Addi-
tionally, increased expression of IL-1α, K16, and filaggrin has 
been found in conjunction with follicular hyperkeratinization, 
and they are thought to be contributing factors.13,14 It is still 
unclear why follicular hyperkeratinization and increased 
keratinocyte proliferation occur in some individuals, but 
not others.
Increased sebum production during puberty is also a 
major contributing factor in the pathogenesis of acne  vulgaris. 
During puberty, androgens play an important role in alter-
ing the sebaceous unit expression in the skin. Sebaceous 
units have been found to contain enzymes that are capable 
of synthesizing androgens from precursor molecules.12 
Additionally, androgens can have a stimulatory effect on 
sebocyte proliferation.15 Interestingly, increased levels of 
lipoperoxides and decreased levels of vitamin E have been 
found in the sebum of acne patients, indicating that there is 
not only excessive sebum production in acne patients, but 
also altered sebum composition.16 Therefore, sebaceous 
gland growth, increased sebum excretion, and altered sebum 
composition likely predispose certain patients toward acne 
pathogenesis.
Follicular obstruction caused by hyperkeratinization in 
conjunction with increased sebum production during puberty 
provides an excellent environment for bacterial growth, 
particularly P. acnes. P. acnes is an anaerobic, Gram-positive 
bacteria that is typically present in normal skin flora, but 
can grow rapidly in areas of obstruction or increased sebum 
production. P. acnes has been found to be highly associated 
with acne and has been found to induce proinflammatory and 
antimicrobial factors, leading to the characteristic inflamma-
tion seen in acne vulgaris.17,18 Because P. acnes is part of the 
body’s natural flora, it is likely that only certain strains with 
the ability to induce changes in immune response predispose 
patients to acne vulgaris.
Another important feature in the pathogenesis of acne vul-
garis is inflammation. The presence of increased inflamma-
tory cytokines is common to all patients with acne vulgaris. 
Inflammation is believed to play an important role in acne 
progression and increases the risk of scarring.19 Follicular 
hyperkertinization, abnormal sebum properties, and the 
 presence of P. acnes all appear to contribute to the production 
of an inflammatory response in acne patients.17 Alterations in 
the immune response and the increased presence of inflam-
matory mediators in acne patients suggest that acne is an 
inflammatory skin disorder, and targeting the inflammatory 
response may improve acne symptoms.
Benzoyl peroxide
BP is often a mainstay in acne treatment regimens today. 
BP has known bactericidal properties.20 An in vitro study 
by Waller et al21 demonstrated that the minimum inhibitory 
concentrations against P. acnes was 128 µg/mL, making it 
an effective agent for targeting P. acnes in the pathogen-
esis of acne vulgaris. The second mechanism of action by 
which BP targets acne is through its keratolytic effects. BP 
has been found to be more effective in disrupting stratum 
corneum cohesion compared to salicylic acid, retinoic acid, 
and  vehicle.21 Additionally, it also has been found to have 
mild anti-inflammatory properties.22 Interestingly, bacterial 
resistance to BP has not been reported, and use of BP in 
combination with topical antibiotics may even reduce the risk 
of P. acnes resistance to these agents as well.2,23,24 Although 
BP can be associated with some dryness and irritation, 
and occasional allergic contact dermatitis, it is generally a 
well-tolerated, safe, and effective topical medication for the 
treatment of acne vulgaris.24
Topical antibiotics
The most common topical antibiotics used for the treat-
ment of acne include clindamycin and erythromycin. These 
antibiotics are used for acne treatment because they target 
P. acnes colonization and proliferation.25 Clindamycin 
and erythromycin are antibiotics that work by targeting 
the 50s subunit of bacterial ribosomes and interfering with 
protein synthesis, thereby exerting antibacterial effects. In 
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addition to antibacterial activities, clindamycin also has 
anti-inflammatory properties. It is well known that P. acnes 
can induce an inflammatory response. Clindamycin has 
been shown to inhibit this P. acnes-driven inflammatory 
response as well as inhibit the expression of proinflam-
matory cytokines, such as IL-1β, IL-6, INF-γ, TNF-α, and 
GM-CSF.26 Additionally, studies have demonstrated that 
clindamycin use can also lead to increased phagocytosis 
and opsonization and an improved inflammatory response.26 
Although these topical antibiotics have been shown to dis-
play considerable success in the treatment of acne vulgaris, 
they are rarely used as a monotherapy because of the risk 
for antimicrobial resistance.25,27
Combination therapy: benzoyl 
peroxide and topical antibiotics
Although topical antibiotics have been shown to be effica-
cious in the treatment of acne vulgaris, a major limitation 
for their use as monotherapy is the associated risk of antimi-
crobial resistance.25,27 Before the introduction of combina-
tion therapy, the emergence of erythromycin-resistant and 
clindamycin-resistant P. acnes in patients receiving topical 
or systemic antibiotics alone was a significant problem.28 
 Therefore, combination therapy utilizing at least two medi-
cations is currently the gold standard for treatment of acne 
vulgaris because it targets more than one factor in acne 
pathogenesis and prevents antimicrobial resistance.2 Topical 
combination therapy can involve the use of several medica-
tions together, such as BP, antibiotics, and retinoids, or may 
be available as fixed-dose combination therapies.
Benzoyl peroxide and erythromycin
The first studies combining BP with a topical antibiotic were 
performed using erythromycin rather than clindamycin. In 
1983, Chalker et al29 sought to determine the efficacy of a 
combination erythromycin 3% and BP 5% gel in comparison 
to either medication alone and vehicle. They found that the 
combination of erythromycin and BP therapy had superior 
efficacy to vehicle and to either medication alone. There was 
also a significant improvement in mean pustule, papule, and 
inflammatory lesion count in the combination therapy group 
compared to vehicle, BP alone, or erythromycin alone.29 Eady 
et al28 also confirmed that combination of BP and erythromycin 
is superior to either product alone, and a checkerboard titra-
tion of BP and erythromycin at varying concentrations was 
used to determine whether this finding was due to synergistic 
antibacterial effects. They concluded that the improved effi-
cacy of this combination therapy was not due to a synergistic 
effect, but rather a result of reducing both antibiotic-sensitive 
and -resistant strains of bacteria as well as its ability to prevent 
selection of antibiotic-resistant variants on the skin of acne 
patients maintaining the efficacy of topical antibiotics.28,30
The mechanism of action of the combination of topical 
antibiotics and BP is likely multifactorial. The combination of 
keratolytic, bactericidal, and anti-inflammatory properties of 
BP and the antibacterial and anti-inflammatory properties 
of topical antibiotics make this treatment useful for both 
inflammatory and noninflammatory acne.
Clindamycin 1.2% and benzoyl peroxide 5%
Similar to erythromycin, several studies involving topical 
combinations of clindamycin and BP demonstrated efficacy 
in treating acne vulgaris and have been found to be superior 
to monotherapy with either medication alone.4–7,31,32 In 1997, 
Lookingbill et al32 performed two double-blind controlled 
clinical trials to determine the efficacy and safety of a com-
bination clindamycin 1.2% and BP 5% gel (clindamycin–BP 
5%) compared to either agent alone and vehicle. Efficacy and 
safety were evaluated at baseline and again at weeks 2, 5, 8, 
and 11. Efficacy was evaluated using inflammatory and non-
inflammatory lesion counts, and safety was evaluated using 
scores for facial erythema, peeling, burning, dryness, and 
pruritus. At week 11, clindamycin–BP 5% had a 66% mean 
reduction in inflammatory and noninflammatory lesions 
compared to 41% reduction in BP-treated patients, 36% 
reduction in clindamycin-treated patients, and 10% reduction 
in those patients treated with the vehicle. Clindamycin–BP 
5% also had a statistically significant improvement in global 
improvement scores. Overall, combination therapy was 
fairly well tolerated, but was associated with mild erythema, 
peeling, and irritation. The rate of these adverse events was 
comparable to BP alone.32
Clindamycin 1.2% and benzoyl  
peroxide 2.5%
Because of concerns for decreased compliance, fixed com-
binations of clindamycin and BP 2.5% have been developed 
to decrease the side effects associated with higher concen-
trations of BP. The major concern regarding reducing or 
changing the concentration of BP was the possibility that 
lower concentrations may be associated with reduced effi-
cacy. However, several studies have demonstrated the clinical 
efficacy of clindamycin–BP 2.5% for the treatment of acne 
vulgaris, indicating that it may be just as effective as 5% and 
10% concentrations for the treatment of acne vulgaris.4,5,31,33 
Additionally, in an in vitro penetration study, Bucks et al34 
found that reducing the BP concentration from 5% to 2.5% 
still maintained a similar amount of total BP delivered to the 





skin, while also leading to a 33% reduction in local irritation, 
thus increasing patient compliance.
A meta-analysis by Seidler and Kimball3 examined 
the efficacy of fixed combination treatments containing 
clindamycin–BP 5% vs clindamycin–BP 2.5%. A Cochrane 
review identified 126 randomized controlled trials in which 
subjects were treated with BP 2.5% or 5% and 1% or 1.2% 
clindamycin. A total of 5,737 patients were included. Of 
them, 1,069 patients were in the clindamycin–BP 5% group 
and 872 patients were in the clindamycin–BP 2.5% group. 
The remainder of the patients received either BP alone, clin-
damycin alone, or vehicle. They found that the combination 
of clindamycin and BP in any concentration was superior to 
either single agent alone in treating inflammatory lesions. 
Clindamycin–BP 2.5% was comparable to clindamycin–BP 
5% in treating acne vulgaris. Interestingly, clindamycin–BP 
2.5% led to a significantly greater absolute reduction in lesion 
count for both inflammatory and noninflammatory lesions 
compared to clindamycin–BP 5%.3 Weighted absolute reduc-
tions in inflammatory and noninflammatory lesion counts 
for clindamycin–BP 5% were 14.81 and 16.83, respectively. 
Weighted absolute reduction in inflammatory and noninflam-
matory lesion counts for clindamycin–BP 2.5% were 25.37 
and 20.83, respectively. It is unclear whether this advantage 
is due to increased efficacy or increased compliance due to 
decreased localized irritation from a lower concentration of 
BP. However, this combination is an effective treatment for 
mild-to-moderate acne vulgaris. Despite the various combi-
nations of clindamycin and BP available, the concentration of 
BP for optimal efficacy and tolerability is still unknown.
Clindamycin phosphate 1.2% and  
benzoyl peroxide 3.75%
Recently, a clindamycin phosphate 1.2% and BP 3.75% fixed 
combination aqueous gel was created as a novel intervention 
for the treatment of moderate-to-severe acne vulgaris. At BP 
3.75%, the combination was designed to have improved effi-
cacy over the clindamycin–BP 2.5%, with increased tolerabil-
ity over the clindamycin–BP 5% combination. Pariser et al35 
evaluated the safety and efficacy of clindamycin–BP 3.75% 
aqueous gel in a study involving 498 patients with moderate-
to-severe acne. Patients with moderate-to-severe acne were 
randomized to clindamycin–BP 3.75% or vehicle.
Results
After 12 weeks of treatment, Pariser et al35 found that 
clindamycin–BP 3.75% was statistically superior to vehicle 
for the treatment of moderate-to-severe acne vulgaris. The 
mean percentage reduction in lesion counts was significantly 
higher in the clindamycin–BP 3.75% group compared to 
vehicle. The mean percentage change from baseline to week 
12 for inflammatory and noninflammatory lesion counts on 
clindamycin–BP 3.75% was 60.6% and 51.6%, respectively. 
The mean percentage change from baseline to week 12 for 
inflammatory and noninflammatory lesion counts on vehicle 
was 31.4% and 27.4%, respectively. Treatment success, 
defined as at least a 2-grade improvement in Evaluator Global 
Severity Score, occurred in 34.3% vs 15.6% in patients 
treated with clindamycin–BP 3.75% compared to patients 
treated with vehicle by the end of the study.
Subjective assessment of efficacy included assessment 
of subject self-assessment (SSA), patient satisfaction survey 
(PSS), degree of oiliness and shininess, and acne-specific 
quality of life questionnaires. 
At the end of the study, an SSA of “clear” or “almost 
clear” was reported in 34.9% of cases in the clindamycin–BP 
3.75% group compared to 17.4% in the vehicle group. More 
importantly, over 96% of patients reported some improvement 
in their acne on SSA following 12 weeks of treatment. Mean 
PSS scores at the end of the study increased from baseline by 
56% in the clindamycin–BP 3.75% group compared to 41% 
in the vehicle group. Additionally, the percent of patients 
reporting “none” to “mild” oiliness and shininess increased 
by week 12 by 22.6% vs 15.6% for clindamycin–BP 3.75% 
and vehicle, respectively. This corresponded with a decrease 
in patients reporting “moderate” to “severe” oiliness or 
shininess. Interestingly, the results of the acne quality of life 
assessment did not show a meaningful difference between 
the two groups at the end of the study.
Limitations
Despite the improvement associated with clindamycin–BP 
3.75% gel, this trial only evaluated this fixed combination 
gel to the vehicle. Therefore, it is impossible to determine 
whether it is superior or inferior to the existing 2.5% or 5% 
combination therapies. In this study, mean improvement after 
12 weeks of treatment with clindamycin–BP 3.75% or vehicle 
was 60.6% vs 31.4% in inflammatory lesions and 51.6% vs 
27.4% in noninflammatory lesions, respectively.35 In a similar 
study using clindamycin–BP 2.5%, the reported reduction 
was 64.1% vs 34.3% in inflammatory lesions and 48.7% vs 
26.0% in noninflammatory lesions with clindamycin–BP 
2.5% and vehicle, respectively.31  Comparative effective-
ness studies of the BP–clindamycin combination thera-
pies have not been performed. Further studies evaluating 
clindamycin–BP 3.75% efficacy and tolerability compared 
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to clindamycin monotherapy, BP monotherapy, and other 
fixed combination medications could be useful.
Clindamycin phosphate 1.2% and 
benzoyl peroxide 3.75% in women
Unlike males who typically outgrow acne with time, a subset 
of female patients may experience acne into adulthood, and 
this may include as much as half of all adult females between 
the ages of 20–29 years.36,37 In this subset of patients, hor-
monal dysregularities such as polycystic ovarian syndrome 
and hyperandrogenism are more common.36 For this reason, 
these patients tend to not respond as robustly to standard acne 
treatments, and gynecological follow-up is often required. 
It is generally accepted that acne in adult females typically 
presents as mild-to-moderate inflammatory acne that is 
usually limited to the jawline, chin, and neck, otherwise 
known as the “U-zone”.36,37 However, in a recent large-scale 
international study, researchers found that almost 90% of 
women with acne did not have it limited to the “U-zone”, 
and a mixed inflammatory and noninflammatory acne was 
the most common presentation.38 These results suggested that 
the presentation of facial acne in adult females might be more 
similar to adolescent acne than once believed.
A subgroup analysis performed by Pariser et al35 in their 
study suggested a slightly greater efficacy for clindamycin–BP 
3.75% in female patients compared to males. The mean 
percentage reduction of noninflammatory lesions at the 
end of the study was 55.7% vs 48.1% in female and male 
patients, respectively. The mean percentage reduction of 
inflammatory lesions at the end of the study was 65.3% vs 
55.8% in female and male patients, respectively.35 Although 
this information suggests that the response of male and 
female patients to clindamycin–BP 3.75% may differ, it 
is unclear whether there is a distinction between acne in 
different sexes or different age groups. Additionally, the 
female patients included in this analysis were not limited 
to those with “U-zone” distributed acne. Further clinical 
trials are necessary to determine whether clindamycin–BP 
3.75% is more effective in female patients and whether the 
pathogenesis of acne in this subset of patients is different 
from other patients.
Conclusion
Acne vulgaris is the most common skin disease worldwide 
and is a frequent source of morbidity for affected patients. 
A significant proportion of treatment options exist for acne 
vulgaris, and combination therapy is commonly employed to 
combat the various causes of acne pathogenesis.  Clindamycin 
in conjunction with BP has become part of the mainstay of 
treatment for patients with inflammatory and noninflammatory 
acne. However, the optimal combination of efficacy and toler-
ability has yet to be determined. Pariser et al35 demonstrated 
that clindamycin–BP 3.75% is safe and effective for the treat-
ment of acne vulgaris, suggesting that this formulation may 
be an effective treatment regimen for affected patients. It is 
clear that this specific combination has the ability to reduce 
both inflammatory and noninflammatory acne lesions and to 
be well tolerated. Further studies would be useful to assess 
comparative effectiveness to other BP–clindamycin products 
and monotherapy antibiotics and BP.
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